KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Deffered Revenue (2016 - 2023)

NovoCure's Non-Current Deffered Revenue history spans 9 years, with the latest figure at $807000.0 for Q2 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 82.23% to $807000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $807000.0, a 82.23% decrease, with the full-year FY2022 number at $2.9 million, down 55.57% from a year prior.
  • Non-Current Deffered Revenue hit $807000.0 in Q2 2023 for NovoCure, down from $1.8 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for NVCR hit a ceiling of $12.1 million in Q4 2020 and a floor of $807000.0 in Q2 2023.
  • Historically, Non-Current Deffered Revenue has averaged $7.0 million across 5 years, with a median of $7.9 million in 2019.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 55.49% in 2020 and later crashed 82.23% in 2023.
  • Tracing NVCR's Non-Current Deffered Revenue over 5 years: stood at $7.8 million in 2019, then soared by 55.49% to $12.1 million in 2020, then tumbled by 46.64% to $6.5 million in 2021, then plummeted by 55.57% to $2.9 million in 2022, then tumbled by 71.96% to $807000.0 in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for NVCR at $807000.0 in Q2 2023, $1.8 million in Q1 2023, and $2.9 million in Q4 2022.